Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/92831
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBranford, S.en
dc.contributor.authorYeung, D.en
dc.contributor.authorRoss, D.en
dc.contributor.authorParker, W.en
dc.contributor.authorBraley, J.en
dc.contributor.authorSeymour, J.en
dc.contributor.authorHughes, T.en
dc.date.issued2014en
dc.identifier.citationAbstract of power point presentation at 56th ASH Annual Meeting, published in Blood, 2014 / vol.124, iss.21, pp.816en
dc.identifier.issn0006-4971en
dc.identifier.issn1528-0020en
dc.identifier.urihttp://hdl.handle.net/2440/92831-
dc.description.statementofresponsibilitySusan Branford, David T Yeung, David M Ross, Wendy T Parker, Jodi Braley, John F Seymour, and Timothy P. Hughesen
dc.language.isoenen
dc.publisherAmerican Society of Hematologyen
dc.rights© 2014 by The American Society of Hematologyen
dc.titleThe adverse effect of high sokal risk for first line imatinib treated patients is overcome by a rapid rate of BCR-ABL decline measured as early as 1 month of treatmenten
dc.typeConference itemen
dc.identifier.rmid0030023652en
dc.contributor.conference56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)en
dc.identifier.pubid170563-
pubs.library.collectionMedicine publicationsen
pubs.library.teamDS01en
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidRoss, D. [0000-0001-7171-2935]en
dc.identifier.orcidHughes, T. [0000-0002-0910-3730]en
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.